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Peptide phosphorodiamidate morpholino oligomers (PPMO) are synthetic DNA mimics that  24 
bind complementary RNA and inhibit bacterial gene expression.  (RFF)3RXB- AcpP PPMO (R,  25 
arginine; F, phenylalanine; X, 6-aminohexanoic acid; B, β-alanine) is complementary to 11  26 
bases of the essential gene acpP (encodes acyl carrier protein).  The MIC of (RFF)3RXB-  27 
AcpP was 2.5 μM (14 μg/ml) in Escherichia coli W3110.  The rate of spontaneous resistance  28 
of E. coli to (RFF)3RXB-AcpP was 4 x 10
-7 mutations/cell division.  A spontaneous  29 
(RFF)3RXB-AcpP-resistant mutant (PR200.1) was isolated.  The MIC of (RFF)3RXB-AcpP  30 
was 40 μM (224 μg/ml) in PR200.1.  The MICs of standard antibiotics were identical in  31 
PR200.1 and W3110.  The sequence of acpP was identical in PR200.1 and W3110.  PR200.1  32 
was also resistant to other PPMOs conjugated to (RFF)3RXB or peptides with a similar  33 
composition or pattern of cationic and non-polar residues.  Genomic sequencing of PR200.1  34 
identified a mutation in sbmA, which encodes an active transport protein.  In separate  35 
experiments, a (RFF)3RXB-AcpP-resistant isolate (RR3) was selected from a transposome  36 
library, and the insertion was mapped to sbmA.  Genetic complementation of PR200.1 or RR3  37 
with sbmA restored susceptibility to (RFF)3RXB-AcpP.  Deletion of sbmA caused resistance to  38 
(RFF)3RXB-AcpP.   We conclude that resistance to (RFF)3RXB-AcpP was linked to the  39 
peptide and not the PMO, dependent on the composition or repeating pattern of amino acids,  40 
and caused by mutations in sbmA.  The data further suggest that (RFF)3R-XB PPMOs may be  41 
transported across the plasma membrane by SbmA.  42 
  43 
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Introduction  45 
Antibiotic resistance in bacteria continues to be a serious problem.  The number of  46 
antibiotic-resistant pathogens is increasing, the level of resistance to standard antibiotics is  47 
increasing, and the percentage of isolates with resistance to multiple antibiotics has risen  48 
dramatically in recent years (3, 37). At the same time, the number of antibiotics that are being  49 
developed has decreased significantly, particularly for those targeting Gram-negative  50 
bacteria.  Most of the new antibiotics that have been approved for use in the United States in  51 
the past 40 years are not new classes of antibiotics, but simply chemical derivatives of the  52 
same antibiotic classes that were discovered in the mid twentieth century (8). There is an  53 
urgent need for new antibiotics particularly for those with novel or innovative strategies of  54 
targeting bacterial pathogens that cause serious diseases (3, 22).  55 
Genomics has created an attractive potential for developing innovative strategies that  56 
address the problem of antibiotic resistance.  Synthetic antisense oligomers, such as peptide  57 
nucleic acids (14), phosphorothioates (16), and phosphorodiamidate morpholino oligomers  58 
(11, 15), silence expression of bacterial genes.  Gene-silencing oligomers decrease  59 
expression of reporter genes such as luciferase, activate endogenous genes such as β- 60 
galactosidase, and inhibit growth and kill bacteria by targeting essential genes (10).   61 
Antisense oligomers targeted to specific, essential bacterial genes reduce infections and  62 
increase survival in mouse models of infection (12, 15, 40).  63 
Antisense oligomers require assistance to cross the outer membrane of Gram-negative  64 
bacteria because of their molecular weight and polar characteristics.  Short amphipathic  65 
peptides have been attached to antisense oligomers, and this has greatly improved their entry  66 
into Gram-negative bacteria and increased their potency (11, 13, 27).   67 4 
 
Membrane-penetrating peptides have diverse sequences, but many are cationic and  68 
amphipathic.  Previous investigations suggest that a repeated peptide motif with one cationic  69 
residue followed by either one or two hydrophobic residues may be an important feature for  70 
efficient membrane penetration (39).  More recently, we have compared a variety of  71 
membrane-penetrating peptides for their abilities to enhance the efficacy of peptide- 72 
phosphorodiamidate morpholino oligomers (PPMO), and found differences among peptides  73 
that vary in their pattern of alternating cationic and nonpolar residues and their amino acid  74 
compositions (27).     75 
Despite the progress that has been made on improving efficacy and potency of  76 
antisense oligomers, little is known about bacterial resistance to these compounds.  Some  77 
naturally-occurring antimicrobial peptides, which have some similar characteristics to the  78 
synthetic peptides used to make peptide-oligomers, do not appear to cause resistance in  79 
bacteria (38).   One report of resistance to an antisense morpholino oligomer found a mutation  80 
in the region of a virus genome targeted by the oligomer (28).  Resistance to any antibiotic is  81 
always an important characteristic to be determined during drug development.  Ultimately the  82 
frequency of antibiotic resistance will manifest itself in the clinic, and will play a role in its use  83 
for any particular indication.  84 
  In this report, we characterize spontaneous resistance to a peptide-PMO (PPMO) and  85 
compare cross-resistance to other antibiotics, PPMOs with different peptides but the same  86 
PMO, and PPMOs with the same peptide but targeted to different genes.  Furthermore, the  87 
same gene that causes PPMO-resistance is identified in isolates from two independent  88 
strategies of selection.   89 
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Material and Methods  91 
  92 
Bacterial strains.  Wild type K-12 E. coli W3110 was used for selecting spontaneous  93 
mutants that are resistant to the PPMO (RFF)3RXB-AcpP.  Spontaneous mutants that are  94 
resistant to (RFF)3RXB-AcpP were selected by growth in Mueller-Hinton II broth  95 
supplemented with at 8 x MIC of (RFF)3RXB-AcpP.  Liquid cultures were grown in either  96 
Mueller-Hinton II or LB broth.  LB agar was used for growth on solid medium.  Transformants  97 
with pSE380myc-luc (11) were grown in LB supplemented with 50 µg/ml ampicillin (Sigma- 98 
Aldrich, St. Louis, MO).  99 
Oligopeptide transport mutants PA0183 (opp), PA0333 (opp dpp), PA0410 (opp tpp),  100 
PA0643 (opp dpp tpp), and PA0610 (opp dpp tpp), which were derived from parent strain  101 
Morse 2034 (trpE9851 leu 277 F
-IN(rrnD–rrnE)), have been described (36) and were gifts  102 
from J. W. Payne (University of Wales, Bangor, UK).  103 
In-frame, non-polar knock-out strains E. coli JW3496 (dctA
-), JW5730 (eptA
-), and   104 
JW0368 (sbmA
-) and their isogenic parent strain BW25113 (2), were provided from the Keio  105 
collection by the National BioResource Project (NIG, Japan).  The knock-out strains were  106 
grown in LB broth with 50 μg/ml kanamycin (Sigma-Aldrich).  The IPTG-inducible sbmA  107 
expression plasmid (which we call pSbmA, from strain b0377) and empty vector control  108 
(pNTR-SD) (34) were also provided by the National BioResource Project (NIG, Japan) and  109 
grown in LB broth with 20 μg/ml ampicillin.  110 
  PPMO.  PPMOs were synthesized at AVI BioPharma (Corvallis, Oregon) as described  111 
(39).  The base sequence of all PPMOs targeted to acpP (AcpP) is 5’-CTTCGATAGTG-3’, to  112 
ftsZ (FtsZ) is 5’-TCCATTGGTTC-3’, and to luc (Luc) is 5’-AACGTTGAGIG. Inosine in place of  113 6 
 
a guanine in the Luc PPMO was necessary to make the oligomer soluble in aqueous solutions  114 
by avoiding guanine quartet structure.  The scrambled base sequence control (Scr) is 5’- 115 
TCTCAGATGGT-3’.  116 
  Antibiotics.  Antibiotics were purchased from Sigma-Aldrich, except bleomycin (Enzo  117 
Life Science, Farmingdale, NY).  118 
Minimal inhibitory concentration.  Minimal inhibitory concentration was determined  119 
by the microdilution method (5) in Mueller-Hinton II broth.  For MICs using XL1-Blue MRF’ and  120 
RR3, Mueller-Hinton II broth was supplemented with 1% tryptone.    121 
Luciferase expression.  Spontaneous (RFF)3RXB-AcpP-resistant mutants were made  122 
chemically competent and transformed as described (29) with pSE380myc-Luc (11).   123 
Overnight cultures were grown aerobically at 37°C in LB medium plus 50 µg/ml ampicillin  124 
(LBA), and then diluted 2 x 10
-2 into LBA with or without various concentrations (8, 20 and 50  125 
μM) of (RFF)3RXB-Luc or (RFF)3RXB-Scr, and grown aerobically at 37°C for 7 h.  Samples  126 
were analyzed for luciferase expression by luminometry as described (11).  127 
Rate of spontaneous resistance.  The rate of spontaneous resistance to peptide- 128 
PMO was measured by the method of Luria and Delbruck (23) as described (33).  An  129 
overnight culture was diluted to 1  10
4 cfu/ml in LB medium and divided into 20  1 ml  130 
aliquots.  Each aliquot was grown overnight at 37°C with aeration, and then 1 μl or 50 µl of  131 
each was spread on 20 agar plates (60 mm  15 mm) of LB plus 20 µM peptide-PMO.  Plates  132 
were grown overnight at 37°C with aeration, and colonies were enumerated.   133 
Screening transposome mutants.  EX-Tn5<R6Kγori/Kan-2>Tnp (Epicentre,  134 
Madison, WI) was electroporated into E. coli XL1-Blue MRF’, and 3 x 10
3 transductants were  135 
selected on LB kanamycin (15 μg/ml) plates.  The transductants were pooled and stored in  136 7 
 
PBS + 15% glycerol at -75°C.  The pooled transductants were thawed and 1 x 10
4 cfu was  137 
spread on an LB plate that included 20 μM (RFF)3RXB-AcpP.   Insertion mutations from  138 
PPMO-resistant mutants were sequenced by rescue cloning as described by the  139 
manufacturer (Epicentre).  Insertions in sbmA were confirmed using polymerase chain  140 
reaction (PCR) as described (18).  Briefly, PCR reactions contained chromosomal DNA  141 
extracted from bacteria using a commercial kit (DNAeasy, Qiagen, Valenica, CA) and primers  142 
(IDT Technologies, Coralville, IA) that flank the insertion site: 5’- 143 
GATTGCCGTTATCTTCTGGC and 5’-GCTCAAGGTATGGGTTACTTCC. Thirty PCR reaction  144 
cycles were: denature, 95°C, 0 sec; anneal 45°C, 0 sec; extend 72°C, 1 min.  PCR reactions  145 
were run on a 1605 air thermo-cycler (Idaho Technology, Idaho Falls, ID).   146 
  Sequencing acpP.  The acpP allele from each strain analyzed was amplified by  147 
polymerase chain reaction (18) using as template a single bacterial colony picked from a  148 
growth plate, Promega Taq polymerase (Madison, WI), and the following primers (Invitrogen,  149 
Carlsbad, CA): 5’-AACGTAAAATCGTGGTAAGACC-3’, and 5’- 150 
TAACGCCTGGTGGCCGTTGATG-3’.  The PCR products were gel-purified using Qiagen  151 
MinElute PCR purification kit (Valencia, CA), and sequenced using the same primers shown  152 
above at the core laboratory of the Center for Genome Research, Oregon State University.   153 
  Genomic sequencing.  Genomic DNA from the W3110 wild type and PR200.1 was  154 
generated by standard procedures (1). DNA was sheared by sonication and processed for  155 
Illumina high-throughput sequencing as previously described (31, 32). Data analyses to find  156 
individual point mutations were carried out as described (32).  157 
  158 
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Results  160 
  Spontaneous mutants resistant to peptide-PMO.  Spontaneous resistance was  161 
apparent from growth that occasionally occurred in some cultures that included (RFF)3RXB- 162 
AcpP (X is 6-aminohexanoic acid and B is β-alanine) at concentrations  above the MIC.   163 
Growth above the MIC was never observed in cultures that included other AcpP PPMOs with  164 
different peptides attached to the same PMO, such as (RX)6B-AcpP or (RXR)4XB-AcpP.  The  165 
rate of spontaneous resistance to (RFF)3RXB-AcpP was measured and found to be 4  10
-7  166 
mutations/cell generation.  167 
  Susceptibility to antibiotics and growth rate.  Colonies were isolated from a single  168 
liquid culture of W3110 grown with 8 × MIC (20 μM = 112 μg/ml) of (RFF)3RXB-AcpP.  One  169 
colony (PR200.1) was picked at random and further characterized.  PR200.1 was equally  170 
susceptible as the parent strain W3110 to each antibiotic tested (MIC = 4 µg/ml, 1.25 µg/ml,  171 
1.25 µg/ml, 0.125 µg/ml, and 10 µg/ml for ampicillin, tetracycline, kanamycin, polymyxin B,  172 
and rifampin, respectively).  These results indicate that this particular PPMO-resistant isolate  173 
was not resistant to antibiotics in general.  174 
  Doubling times of PR200.1 and W3110 were identical and no difference in growth rate  175 
was observed in liquid or solid media.  176 
Sequences of acpP alleles.  The target of the PMO, acpP, was sequenced in  177 
PR200.1 and W3110 and found to be identical (data not shown).  178 
  MICs of AcpP PPMOs attached to various peptides.  MICs for different AcpP  179 
PPMOs were measured using PR200.1 and W3110 as indicators (Table 1).  All of the AcpP  180 
PPMOs tested had the same base sequence, but had different peptides attached.  The  181 
attached peptides differed not only in their amino acid compositions, but also in the pattern of  182 9 
 
repeating sequences of cationic and nonpolar residues.  Repeating patterns of amino acids,  183 
often including cationic and non-polar residues, are important features of membrane- 184 
penetrating peptides (17, 41, 42).  Four of the AcpP PPMOs, including (RFF)3RXB-AcpP, had  185 
peptides with a repeating amino acid motif of cationic-nonpolar-nonpolar (C-N-N), and one of  186 
these was composed of D- instead of the usual L-amino acids .  One AcpP PPMO was  187 
conjugated to (RX)6B, which has a repeating motif of cationic-nonpolar (C-N).  Two other  188 
AcpP PPMOs were conjugated to peptides with a repeating motif of cationic-nonpolar-cationic  189 
(C-N-C): (RXR)4XB or (RFR)4XB.  Another AcpP PMO was conjugated to RTRTRFLRRTXB,  190 
which does not conform to any of the other repeat patterns.  All of these PPMOs with various  191 
peptides attached to the same AcpP PMO have been previously characterized and found to  192 
be effective in inhibiting growth of E. coli (27).    193 
 The results show that PR200.1 was resistant to every AcpP PMO tested with the C-N- 194 
N peptide motif, but was fully susceptible to (RX)6B-AcpP PMO and (RXR)4XB-AcpP PMO  195 
(Table 1).  However, PR200.1 was resistant to (RFR)4XB-AcpP, which shares the C-N-C motif  196 
with (RXR)4XB-AcpP, but like (RFF)3RXB-AcpP contains phenylalanine instead of 6- 197 
aminohexaonoic acid.  Compared to the susceptible parent strain W3110, resistance to  198 
(RFF)3RXB-AcpP in PR200.1 increased the MIC 16-fold.  PR200.1 was also resistant to the  199 
D-isomeric form of (RFF)3RXB.  The MIC of RTRTRFLRRTXB-AcpP, which lacks a repeating  200 
amino acid motif but includes one phenylalanine, increased only 2-fold using PR200.1  201 
compared to W3110 as indicator.  The MICs of scrambled-base sequence PPMOs composed  202 
with each of the same peptides used for the AcpP PPMOs were undetectable (>80 μM) in  203 
every case.  204 10 
 
  (RFF)3RXB-PPMOs targeted to various genes.  PR200.1 was tested for susceptibility  205 
to two PPMOs, each with the (RFF)3 peptide motif, but different base sequences.  One PPMO  206 
is complementary to ftsZ, which is an essential gene involved in cell division.  The other  207 
PPMO is targeted to a luciferase reporter gene (luc).  208 
Exponential cultures were grown for 18 h with (RFF)3RXB-FtsZ, which is targeted to  209 
ftsZ, or a scrambled (Scr) base sequence control.  Samples of each culture were then plated,  210 
and viable cells counted.  PR200.1 grew to normal cell density, whereas the viable cell count  211 
of the parent strain W3110 was reduced by over 2 orders of magnitude in the presence of  212 
(RFF)3RXB-FtsZ (Figure 1).  The Scr had no effect on growth of either W3110 or PR200.1.    213 
In other experiments, exponential cultures of W3110 and PR200.1 were grown for 7 h  214 
with various concentrations of (RFF)3RXB-Luc, which is targeted to a luciferase reporter gene,  215 
or the scrambled base control (RFF)3RXB-Scr.  A plasmid that expresses luciferase had been  216 
transferred into PR200.1 prior to the experiment.  Samples of each culture were then  217 
analyzed by luminometry for luciferase activity.  The results show that (RFF)3RXB-Luc did not  218 
inhibit luciferase in PR200.1 at any of the 3 concentrations tested (Figure 2).  In comparison,  219 
W3110 showed inhibition of luciferase that was proportional to the concentration of PPMO  220 
added.  The scrambled sequence control did not inhibit luciferase in either strain.  There were  221 
no differences in the growth (optical density) of any of the cultures (data not shown).  222 
Peptide transport mutants.  The above results indicated that resistance to PPMOs is  223 
linked to the peptide moiety.  We hypothesized that PPMO-resistance could be caused by a  224 
mutation in one of three known oligopeptide transporters.  To test this, the MIC was measured  225 
using various strains with mutations in one, two, or all three oligopeptide transporters (Table  226 11 
 
2).  The results show that (RFF)3RXB-AcpP had the same MIC in PR200.1 as the parent  227 
(non-mutant) strain.  (RFF)3RXB-Scr scrambled control showed no detectable MIC (>160 μM).  228 
  Genomic sequencing.  The genomes of PR200.1 and its parent strain W3110 were  229 
sequence and compared.  The results indicated that a total of 3 genes had mutations in  230 
PR200.1 compared to W3110: dctA, eptA, and sbmA.  In dctA, there were 2 transition  231 
mutations at bases 3958154 (T→A) and 395153 (A→G), both of which are in codon 396, that  232 
caused a missense from ile to ala.  In eptA, there was one transversion mutation at base  233 
4339795 (T→A) that affected codon 259 and caused a missense from ser to thr.  In sbmA,  234 
there was one transversion mutation at base 396121 (T→G) that changed codon 87 (ser to  235 
ala).  No deletions or insertions were detected in any gene.  236 
  Characterize deletion mutants.  In frame knock-out mutants of dctA, eptA, and sbmA  237 
were tested for susceptibility to (RFF)3RXB-AcpP and compared to the parent strain  238 
(BW25113).  The MIC of (RFF)3RXB-AcpP was the same (2 μM = 11 μg/ml) using either the  239 
dctA
- or eptA
- knock-out strains or the parent strain.  The MIC using the sbmA
- strain was 32  240 
μM (179 μg/ml).  241 
  The MIC of (RXR)4XB-AcpP was measured using sbmA
- strain as indicator, and found  242 
to be 2 μM (11 μg/ml), the same as its isogenic parent strain.  243 
  Complementation with pSbmA.  PR200.1 was genetically complemented with an  244 
IPTG-inducible expression plasmid that encodes sbmA (pSbma), or its empty control.  The  245 
complemented strain was grown with IPTG and used to measure the MIC of (RFF)3RXB- 246 
AcpP.  The MIC was 1 μM and 32 μM in the induced, sbmA
+ complemented strain and the  247 
empty vector control strain, respectively.    248 12 
 
  Transposome mutants.  E. coli XL1-Blue MRF’ was mutagenized with the  249 
transposome EZ-Tn5 and a library of 1 x 10
4 mutants was spread on selection plates that  250 
included 20 μM (RFF)3R-AcpP.  Two colonies grew on the selection plate, and the mutated  251 
gene in each was sequenced.  The sequences of both isolates indicated that the transposome  252 
had inserted into the exact same position in sbmA in each isolate, suggesting that the two  253 
colonies were clones.  The isolates were named RR3.  254 
  RR3 was characterized by measuring the MICs of various standard antibiotics (Table  255 
3).  All standard antibiotics tested had the same MIC using either XL1-Blue MRF’ or RR3 as  256 
indicator, including two peptide antibiotics colistin and polymyxin B.  However, RR3 was about  257 
4-fold resistant to each of the peptide antibiotics bleomycin and phleomycin.   PR200.1 was  258 
also 4-fold resistant to bleomycin (MIC = 5.6 μM [8 ug/ml]) and phleomycin (MIC = 5.2 μM [8  259 
μg/ml]) compared to W3110 (bleomycin MIC = 1.4 μM [2 μg/ml]; phleomycin MIC = 1.3 μM [2  260 
μg/ml]).    261 
  The MICs of (RFF)3R-AcpP and (RXR)4XB-AcpP were measured using RR3 or XL1- 262 
Blue MRF’ as indicators.  The results show that RR3 was 32-fold resistant to (RFF)3RXB- 263 
AcpP, and 8-fold resistant to (RXR)4XB-AcpP (Table 3).  RR3 was also resistant to the PPMO  264 
made with D-amino acids ([D-(RFF)3R]XB-AcpP).  Scrambled-sequence control PPMOs did  265 
not inhibit growth of either RR3 or XL1-Blue MRF’.  266 
  RR3 and XL1-Blue MRF’ were genetically complemented with pSbmA and used to  267 
measure the MIC of (RFF)3RXB-AcpP.  pSbma fully restored susceptibility of RR3 to the  268 
PPMO, when induced with IPTG (Table 3).  Interestingly, the MIC was significantly less using  269 
the complemented strains as indicators compared to the strains without pSbmA.   270 
Complementation with pSbmA also restored susceptibility to bleomycin and phleomycin.  271 13 
 
  272 
Discussion  273 
  This is the first report we are aware of to characterize bacterial resistance to an  274 
antisense antibacterial compound.  Initially, growth was occasionally and unexpectedly  275 
observed during routine MIC assays of (RFF)3XB-AcpP in cultures 4- to 8-fold above the MIC.  276 
Similar growth was never observed during MIC assays for (RXR)4XB-AcpP or (RX)6B-AcpP.   277 
We speculate that the greater number of X residues (6-aminohexanoic acid) or the lack of F in  278 
the latter two PPMOs may be responsible for the apparent lack of spontaneous resistance to  279 
these PPMOs under the conditions used for the MIC assay.  Alternatively, there could be  280 
more genetic loci involved in resistance to (RFF)3RXB PPMOs than in any (putative)  281 
resistance to PPMOs conjugated to other peptides such as (RXR)4XB or (RX)6B.  However,  282 
we have not yet rigorously pursued resistance to these later PPMOs, and it is certainly  283 
possible that spontaneous resistance may occur under appropriate conditions.  284 
  The rate of spontaneous resistance to (RFF)3RXB-AcpP was similar to the rate of  285 
spontaneous mutation for individual genes in E. coli, which is typically between 10
-6 to 10
-7  286 
mutations/gene/ generation (6, 24).  This suggests that there are few genes which, when  287 
mutated, can give rise to the PPMO-resistant phenotype.  However, the rate of mutation can  288 
vary widely, and any measurement of the rate of mutation is a function of many variables (25),  289 
including the concentration of antibiotic used for selection, and the number of genes or loci  290 
capable of causing a resistance phenotype.  Ultimately, the rate of resistance to PPMOs  291 
under in vivo conditions for specific infections will be the most meaningful measure of their  292 
usefulness in the clinic.   293 14 
 
  The spontaneous mutant PR200.1 was susceptible to all small molecule antibiotics  294 
tested.  This shows that resistance to the PPMO is not caused by a change in physiology that  295 
might result in resistance to antibiotics in general.  Such general changes are known to occur,  296 
and include a reduction of the net negative charge of the lipopolysaccharide of Gram-negative  297 
bacteria (7, 30), changes in capsule polysaccharide (4), changes in expression of outer  298 
membrane porins (30), alterations in outer membrane lipid composition that results in  299 
decreased membrane permeability (30), and activation or overexpression of multidrug efflux  300 
pumps (21).  We tested a variety of antibiotics, some of which are hydrophilic (ampicillin,  301 
kanamycin), hydrophobic (rifampin, tetracycline), or amphiphilic (polymyxin B), and some  302 
which enter Gram-negative bacteria through the outer membrane porins (ampicillin,  303 
tetracycline) or through the outer membrane lipid bilayer (rifampin, polymyxin B).  The results  304 
suggested that the mutation in PR200.1 is specific for (RFF)3RXB-AcpP or PPMOs with  305 
similar peptide moieties.  Later, following the identification of the mutation in sbmA, PR200.1  306 
was found to be mildly resistant (4-fold) to the peptide antibiotics bleomycin and  phleomycin.   307 
  We hypothesized that resistance was caused by a mutation in the sequence of acpP  308 
targeted by the PPMO.  We have previously shown that a one-base mismatch near the 3’end  309 
of a PPMO targeted to acpP in Burkholderia cepacia complex raised the MIC by a factor of at  310 
least 8-32-fold (15).  However, the results in the present report found no mutation in the target  311 
region of acpP in this one resistant mutant.  Therefore, the hypothesis in this case was  312 
disproven.  However, this is not to say that target site mutations cannot or do not occur on  313 
other as of yet uncharacterized mutants.  Nevertheless, target site mutations would be  314 
statistically improbable considering that there are only 4 wobble bases in the target region of  315 15 
 
acpP that might possibly lead to a decrease in efficacy without changing the amino acid  316 
sequence of the targeted protein.   317 
Another hypothesis was that resistance in PR200.1 was caused by a mutation in an  318 
oligopeptide transporter.  However, oligopeptide transport mutants were just as susceptible to  319 
(RFF)3RXB-AcpP as the isogenic parent strain.  This showed that resistance in PR200.1 was  320 
not caused by a mutation in the known oligopeptide transporters that were tested.  321 
In another effort to identify the mutation in PR200.1 that is responsible for resistance to  322 
(RFF)3RXB-AcpP, the genome of PR200.1 was sequenced.  The results showed missense  323 
mutations in only 3 genes compared to the PPMO-susceptible strain: dctA, eptA, and sbmA.    324 
In-frame, non-polar deletion mutations of each gene showed that of the three, only the sbmA  325 
deletion strain was resistant to (RFF)3RXB-AcpP.  Furthermore, complementation of PR200.1  326 
with sbmA restored susceptibility to the PPMO.  These results show that mutations in sbmA  327 
cause resistance to (RFF)3RXB-AcpP.  328 
The MIC of (RFF)3RXB-AcpP was slightly lower using the sbmA deletion strain than  329 
PR200.1 as indicator.  However, the strains originated from different parent strains, and this  330 
probably accounts for the difference in susceptibility.  The parent strain of the sbmA deletion  331 
was also slightly more susceptible to the PPMO than the parent strain of PR200.1.  332 
The transposome mutant RR3 was resistant to both (RFF)3RXB-AcpP and (RXR)4XB- 333 
AcpP.  This differs from the spontaneous mutant PR200.1 and the sbmA deletion strain,  334 
which were resistant to (RFF)3RXB-AcpP but not (RXR)4XB-AcpP.  This suggests that a polar  335 
affect in RR3 on the gene downstream from sbmA (yaiW) may be responsible for resistance  336 
to (RXR)4XB-AcpP.   yaiW is a predicted DNA-binding transcriptional regulator.  Apparently a  337 
mutation in sbmA is sufficient to cause resistance to (RFF)3RXB-AcpP, but not (RXR)4-AcpP.  338 16 
 
PR200.1 was susceptible to (RXR)4XB-AcpP but resistant to (RFR)4XB-AcpP, although  339 
these two PPMOs share the same C-N-C repeat motif.  This indicates that the amino acid  340 
composition of the PPMOs may be more important than the repeating pattern of amino acids  341 
in determining resistance in PR200.1.  The similarity in resistance of PR200.1 to either  342 
(RFF)3RXB-AcpP or (RFR)4XB-AcpP, but complete susceptibility to (RXR)4XB-AcpP may  343 
suggest that X (6-aminohexanoic acid) accounts for the difference.  This is supported by the  344 
result (Table 1) that resistance to (RXX)3RXB-AcpP is 4-fold less than resistance to  345 
(RFF)3RXB-AcpP, despite having the same repeating pattern of cationic and non-polar amino  346 
acids, but containing more X.  Perhaps the unusual 6-carbon backbone of X causes a  347 
conformational change that disallows interaction with SbmA.  Alternatively, sbmA mutants  348 
seem to be more resistant to peptides with F (phenylalanine).  There is a positive trend  349 
between the number of F in the peptide and resistance.  This is supported by the results that  350 
show higher resistance to PPMOs with more F (such as (RFF)3RXB-AcpP and (RFR)4XB- 351 
AcpP), lesser resistance to PPMOs with fewer F (such as RTRTRFLRRTXB-AcpP), and no  352 
resistance to PPMOs with no F (such as (RXR)4XB-AcpP and (RXR)6XB-AcpP), although  353 
(RXX)3RXB-AcpP is an exception to this trend.  354 
sbmA encodes an active transporter for bleomycin and other peptide antibiotics (19,  355 
26, 35, 43).  Our results are consistent with SbmA acting as the active transporter for  356 
(RFF)3RXB-AcpP.  sbmA homologs are widely conserved among bacteria (9).  The homolog  357 
of sbmA in Rhizobium meliloti, bacA, is required for symbiosis with alfalfa (9).  The homolog in  358 
Brucella abortus is a virulence factor important for intracellular survival in macrophages (20).  359 
It has been proposed that the physiological substrates of SbmA are organic signaling  360 17 
 
molecules (43).  Development of an assay to measure uptake of PPMOs is currently not  361 
available, but could be used to define further the role of SbmA in resistance to PPMO.  362 
The substrate specificity of SbmA has been investigated and found to be quite flexible.    363 
Initially, the specificity was proposed to be associated with a thiazole or oxazole structural  364 
motif (43).  Later, proline-rich antimicrobial peptides were shown to be transported by SbmA  365 
(26).  However, (RFF)3RXB-AcpP has none of these structural features.  If SbmA is the  366 
transporter of (RFF)3RXB-AcpP, apparently the specificity of SbmA is not limited to thiazole-  367 
or oxazole-containing compounds or to proline-rich peptides.  Our results suggest that the  368 
substrate specificity of SbmA is flexible enough to accommodate polypeptides without  369 
thiazole, oxazole, or proline.  With the peptides we used in our conjugates, the specificity  370 
appears to be linked to the spacing of cationic and non-polar amino acid residues within the  371 
context of the peptide.  It is also noteworthy that our all-D enantiomer conjugate (NG-05-0653)  372 
had the same MIC values as the all-L conjugate (NG-05-0200) for parental and resistant  373 
strains.  This is in contrast to results shown for an all-D isomer of the proline-rich antimicrobial  374 
peptide Bac7(1-35), which was ineffective compared to the all-L form (26).  It was suggested  375 
that the stereospecificity of Bac7(1-35) was attributable to its interaction with SbmA, although  376 
uptake of all-D Bac7(1-35) was not demonstrated.  Perhaps the stereospecificity of Bac7(1-35)  377 
is caused by its interaction with its cytoplasmic target and not SbmA.  Our results suggest that  378 
the specificity of SbmA is not necessarily limited to either the L- or D-enantiomeric form of a  379 
peptide, and is broader than previously known.  380 
If SbmA is the plasma membrane transporter for (RFF)3R-AcpP, we speculate that  381 
other mechanisms exist for PPMOs to cross the plasma membrane.  PR200.1, RR3, and the  382 
sbmA deletion strain are still somewhat susceptible to (RFF)3RXB-AcpP, albeit at high  383 18 
 
concentrations.  We speculate that PPMOs may be able to cross the plasma membrane by  384 
passing through the lipid bilayer in the same manner that they cross the outer membrane.   385 
There also may be additional active transporters with specificities for nucleic acid oligomers.   386 
This latter possibility is suggested by the ability of PMOs (not conjugated to a peptide) to  387 
inhibit gene expression in strains with porous outer membranes that allow passage of large  388 
oligomers (11, 12).  389 
In summary, the results suggest that bacterial resistance to a PPMO can be  390 
determined by the peptide and not the PMO.  The rate of occurrence of spontaneous  391 
resistance to (RFF)3RXB-AcpP is similar to that of spontaneous changes in other bacterial  392 
phenotypes.  In PR200.1 and RR3, resistance is caused by mutations in sbmA.  Our results in  393 
combination with the known role of SbmA in peptide antibiotic uptake, suggest that SbmA acts  394 
as a transporter of (RFF)3RXB-AcpP from the periplasm to the cytoplasm.      395 
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Figure 1.  Viable Cell Count of 18 h Cultures.  Stationary cultures of W3110 or PR200.1  568 
were diluted to 5 x 10
5 CFU/ml in Mueller-Hinton broth and divided in three.  (RFF)3RXB-FtsZ  569 
(FtsZ) or scrambled (Scr) PPMO (160 μM), or no PPMO was added.  Cultures were grown  570 
aerobically at 37°C for 18 h, and then samples of each were diluted and plated to determine  571 
viable cells.  Error bars indicate standard deviation.  *indicates highly significant (P < 0.01)  572 





























































  575 
Figure 2.  Luciferase Activity of Cultures Treated with PPMO.  Growing cultures were  576 
treated for 7 h without PPMO (No PPMO), or with 3 concentrations of a PPMO [(RFF)3RXB- 577 
Luc] targeted to a luciferase reporter gene, or a scrambled sequence control [(RFF)3RXB- 578 
Scr].  After 7 h samples of each culture were measured for luciferase activity by luminometry.   579 
The experiment was repeated 3 times and the error bars indicate standard deviation.   580 
*indicates a highly significant (P < 0.01) difference compared to cultures of PR200.1 with the  581 
same concentrations of (RFF)3RXB-Luc, the cultures of W3110 with the same concentrations  582 
of (RFF)3RXB-Scr, or the culture without PPMO.  583 28 
 
Table 1.  MIC of AcpP PPMO in Pure Cultures of E. coli  
 
PPMO No. NG- 
 
Conjugated Peptide* 
MIC (µM [μg/ml]) 
W3110  PR200.1 
Motif 1 
(C-N-N)** 
       
05-0200  RFFRFFRFFRXB    2.5 [14]  40 [222] 
05-0653  DRDFDFDRDFDFDRDFDFDRXB  2.5 [14]  40 [222] 
23-248  RXXRXXRXXRXB  20 [102]  80 [204] 
06-0199  KFFKFFKFFKXB  10 [54]  80 [435] 
       
Motif 2 
(C-N)** 
     
06-0073  RXRXRXRXRXRXB   1.25 [7]   1.25 [7] 
       
Motif 3 
(C-N-C)** 
     
06-0076  RXRRXRRXRRXRXB   1.25 [7]  1.25 [7] 
07-0795  RFRRFRRFRRFRXB  1 [6]  16 [94] 
       
No Motif       
05-0246  RTRTRFLRRTXB   20 [111]  40 [111] 
*X is 6-amino-hexanoic acid.  B is β-alanine.  O is ornithine.  D indicates the isomeric 
form or the residue that follows. 
**Motif 1 is (cationic-nonpolar-nonpolar, abbreviated C-N-N).  Motif 2 is (cationic-
nonpolar, abbreviated C-N).  Motif 3 is (cationic-nonpolar-cationic, abbreviated C-N-C). 29 
 
Table 2.  MIC of (RFF)3R-AcpP (NG-05-0200) Using Oligopeptide Transport Mutants 
E. coli strain  Mutation/Phenotype 
MIC 
µM  μg/ml 








dipeptide permease deletion 





tripeptide permease mutant 




Table 3.  MIC of standard antibiotics and PPMOs using transposome mutant RR3, isogenic parent strain XL1-Blue MRF’, 
and their sbmA complemented strains 
    MIC (μM [μg/ml]) 
  Antibiotic  XL1-Blue MRF’  RR3  XL1-Blue MRF’ (pSbmA)  RR3 (pSbmA) 
  Polymyxin B  0.8 [1]  0.8 [1]  0.8 [1]  0.8 [1] 
  Colistin  0.9 [1]  0.9 [1]  0.9 [1]  0.9 [1] 
  Erythromycin  34 [25]  34 [25]  34 [25]  34 [25] 
  Rifampin  6 [5]  6 [5]  6 [5]  6 [5] 
  Bleomycin  0.2 [0.25]  0.7 [1]  0.01 [0.016]  0.01 [0.016] 
  Phleomycin  0.3 [0.5]  1.3 [2]  0.02 [0.03]  0.02 [0.03] 
           
PPMO No. NG-  PPMO         
05-0200  (RFF)3RXB-AcpP  2 [11]  64 [355]  2 [11]  2 [11] 
05-0653  [D-(RFF)3R]XB-AcpP  2 [11]  64 [355]  2 [11]  2 [11] 
06-0076  (RXR)4XB-AcpP  1 [6]  8 [48]  0.1 [0.6]  0.1 [0.6] 
05-0655  (RFF)3RXB-Scr  >128 [>714]  >128 [>714]  >128 [>714]  >128 [>714] 
06-0078  (RXR)4XB-Scr  >128 [>714]  >128 [>714]  >128 [>714]  >128 [>714] 31 
 
 